Back to results
US 12,590,106 B2Granted
Spiromacrocyclic orexin 2 receptor agonists
AssigneeH. Lundbeck A/S
InventorsKarsten Juhl, Wanwan Yu, Thomas Leegaard Andersen, Erhad Ascic, Michael Baek, Gitte Kobberøe Mikkelsen, Andreas Michael Arnold, Anders Højgaard Hansen, Petra Lindovská, Henrik Juhani Keränen, Ferran Planas Padrós
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel spiro-macrocyclic compounds of general formula (I) which are Orexin 2 receptor agonists.
Claims18
A compound selected from the group consisting of:
- N-[(1′S,14R)-6,19-difluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide;
- N-[(1′S,14R)-19-chloro-6-fluoro-spiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide;
- N-[(1′S,14R)-6,19-difluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]ethanesulfonamide;
- N-[(1′S,14R)-6,19-difluoro-11-methyl-spiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide;
- N-[(1′S,14R)-4,6,17,19-tetrafluorospiro[8,12-dioxa-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide;
- and
- N-[(1′S,14R)-6,17,19-trifluorospiro[8-oxa-12-thia-21-azatetracyclo[14.3.1.110,13.02,7]henicosa-1(19),2,4,6,10,13(21),16(20),17-octaene-14,3′-cyclopentane]-1′-yl]methanesulfonamide;
- or a pharmaceutically acceptable salt thereof.
5 more elements
A compound selected from the group consisting of:
Dependencies are inferred from the claim text.